European Commission Approves Darzalex Subcutaneous Monotherapy for High-Risk Smoldering Multiple Myeloma (https://www.myeloma.org/news-events/multiple-myeloma-news/european-commission-approves-darzalex-subcutaneous-monotherapy-high-risk-smoldering-multiple)